Cargando…

Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma

MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88(L265P) alone may not be sufficient to induce tumor formation. Interplay between MYD88(L265P) and other genetic events is further supported by the fact that TNFAIP3 (A2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wenzl, Kerstin, Manske, Michelle K., Sarangi, Vivekananda, Asmann, Yan W., Greipp, Patricia T., Schoon, Hanna R., Braggio, Esteban, Maurer, Matthew J., Feldman, Andrew L., Witzig, Thomas E., Slager, Susan L., Ansell, Stephen M., Cerhan, James R., Novak, Anne J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177394/ https://www.ncbi.nlm.nih.gov/pubmed/30301877 http://dx.doi.org/10.1038/s41408-018-0130-3

Ejemplares similares

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
por: Manso, B A, et al.
Publicado: (2017)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma
por: Elbaz, Osama, et al.
Publicado: (2023)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance
por: Wang, James Q., et al.
Publicado: (2014)

MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
por: Narasimhan, Sandhya, et al.
Publicado: (2020)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
por: Mori, Naoki, et al.
Publicado: (2013)

Droplet Digital PCR Assay for MYD88(L265P): Clinical Applications in Waldenström Macroglobulinemia
por: Lo Schirico, Mariella, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
por: Kim, Jung-Ah, et al.
Publicado: (2014)

MYD88(L265P) Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
por: Ferrante, Martina, et al.
Publicado: (2021)

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling
por: Hildebrand, Joanne M., et al.
Publicado: (2010)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

PB2355: CORRELATION OF MYD88 AND TNFAIP3 MUTATIONS WITH CLINICO-HEMATOLOGICAL PROFILE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Shaat, Rana, et al.
Publicado: (2023)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
por: Lynch, Ryan C., et al.
Publicado: (2017)

Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
por: Drandi, Daniela, et al.
Publicado: (2018)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

伴MyD88 L265P突变淋巴浆细胞疾病患者的临床特征分析
Publicado: (2016)

Effectiveness of digital PCR for MYD88(L265P) detection in vitreous fluid for primary central nervous system lymphoma diagnosis
por: Chen, Kun, et al.
Publicado: (2020)

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2023)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

TNFAIP3, TNIP1, and MyD88 Polymorphisms Predict Septic-Shock-Related Death in Patients Who Underwent Major Surgery
por: Jiménez-Sousa, Maria Ángeles, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v9ansfsqpr3fi5p5661i5pv4us